Hims & Hers Health, Inc. reported a second-quarter 2026 earnings per share (EPS) loss of $0.10, missing the expected loss of $0.05. However, the company exceeded revenue expectations with $753.21 million, above the $698.89 million estimate, driven by subscriber growth and expanded personalized healthcare services. Despite the quarterly loss, Hims & Hers raised its annual revenue forecast to $3.1-$3.3 billion, signaling confidence in future growth. Financial ratios show a mixed picture, with a high debt-to-equity ratio of 4.77 and a current ratio below 1, indicating some financial leverage and liquidity concerns.
Rosen Law Firm has filed a class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' health information with third-party advertisers and charging for prescriptions prematurely. The lawsuit claims these actions misled inve...
Hims & Hers Health, Inc. is under investigation following a lawsuit filed by the FTC and state authorities alleging the company misled consumers by charging for prescriptions immediately after intake forms and making subscription cancellations diffic...
The FDA issued warnings to telehealth companies and compounding pharmacies about the use of unapproved compounded weight-loss drugs, including versions of semaglutide, tirzepatide, and retatrutide. Hims & Hers Health shares fell 3.2% following the an...
The Federal Trade Commission, along with California and Utah consumer protection agencies, sued Hims & Hers Health, Inc. for allegedly charging customers immediately after intake forms without clear disclosure and making subscription cancellations di...
